Biotech NewsCEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer BioTech Health XSeptember 16, 2024 CEL-SCI Corporation (NYSE American: CVM) has announced new breakthrough data from its Phase 3 trial of Multikine®, an… 0 Shares 0 0 0 0 0 0 0